Listed

Reviva Pharmaceuticals Holdings, Inc.

RVPHOTCCIK 1742927HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$2.6m, Q2 FY2026
Net income−$2.4m, Q2 FY2026
Reviva Pharmaceuticals Holdings, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m9.6Research and development, Q3 FY2023, three months to 2023-09-30$9.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure8.1Research and development, Q4 FY2023, three months to 2023-12-31$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure5.8Research and development, Q1 FY2024, three months to 2024-03-31$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure5.6Research and development, Q2 FY2024, three months to 2024-06-30$5.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure6.9Research and development, Q3 FY2024, three months to 2024-09-30$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure4.7Research and development, Q4 FY2024, three months to 2024-12-31$4.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure4.1Research and development, Q1 FY2025, three months to 2025-03-31$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure3.7Research and development, Q2 FY2025, three months to 2025-06-30$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure2.1Research and development, Q3 FY2025, three months to 2025-09-30$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure1.7Research and development, Q4 FY2025, three months to 2025-12-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure1.4Research and development, Q1 FY2026, three months to 2026-03-31$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure1.4Research and development, Q2 FY2026, three months to 2026-06-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Operating income$m(11.6)Operating income, Q3 FY2023, three months to 2023-09-30−$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure(9.6)Operating income, Q4 FY2023, three months to 2023-12-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure(7.9)Operating income, Q1 FY2024, three months to 2024-03-31−$7.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure(8.1)Operating income, Q2 FY2024, three months to 2024-06-30−$8.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure(8.5)Operating income, Q3 FY2024, three months to 2024-09-30−$8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(6.3)Operating income, Q4 FY2024, three months to 2024-12-31−$6.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(6.5)Operating income, Q1 FY2025, three months to 2025-03-31−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(6.1)Operating income, Q2 FY2025, three months to 2025-06-30−$6.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure(4.0)Operating income, Q3 FY2025, three months to 2025-09-30−$4.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(3.6)Operating income, Q4 FY2025, three months to 2025-12-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(3.3)Operating income, Q1 FY2026, three months to 2026-03-31−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(2.6)Operating income, Q2 FY2026, three months to 2026-06-30−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$5.9k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-14, accession 0001437749-23-031973.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$13.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$3.5k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$5.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$5.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$4.7k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$11.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$4.8k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$2.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(0.0)Interest expense, Q4 FY2025, three months to 2025-12-31−$5.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2026, three months to 2026-03-31$6.7k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure0.0Interest expense, Q2 FY2026, three months to 2026-06-30$2.9k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$12.1k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure(0.0)Income tax, Q4 FY2023, three months to 2023-12-31−$4.6k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$7.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$7.4k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$4.7k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$5.2k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$8.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$2.8k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$2.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$3.3k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$2.6k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Net income$m(11.3)Net income, Q3 FY2023, three months to 2023-09-30−$11.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure(9.4)Net income, Q4 FY2023, three months to 2023-12-31−$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure(7.4)Net income, Q1 FY2024, three months to 2024-03-31−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure(7.9)Net income, Q2 FY2024, three months to 2024-06-30−$7.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure(8.4)Net income, Q3 FY2024, three months to 2024-09-30−$8.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(6.3)Net income, Q4 FY2024, three months to 2024-12-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(6.4)Net income, Q1 FY2025, three months to 2025-03-31−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(6.1)Net income, Q2 FY2025, three months to 2025-06-30−$6.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure(4.0)Net income, Q3 FY2025, three months to 2025-09-30−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(3.4)Net income, Q4 FY2025, three months to 2025-12-31−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(3.2)Net income, Q1 FY2026, three months to 2026-03-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(2.4)Net income, Q2 FY2026, three months to 2026-06-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Diluted EPS$ per sharenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Basic EPS$ per share(0.48)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figurenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure(0.26)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure(0.25)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figurenot reported(2.61)Basic EPS, Q1 FY2025, three months to 2025-03-31−$2.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(2.40)Basic EPS, Q2 FY2025, three months to 2025-06-30−$2.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure(0.06)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figurenot reported(0.46)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(0.19)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure

Balance sheet

Cash and equivalents$19.9m, Q2 FY2026
Shareholders' equity$15.2m, Q2 FY2026
Reviva Pharmaceuticals Holdings, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m5.0Cash and equivalents, Q3 FY2023, at 2023-09-30$5.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001437749-23-031973.Report this figure23.4Cash and equivalents, FY2023, at 2023-12-31$23.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figure12.0Cash and equivalents, Q1 FY2024, at 2024-03-31$12.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure6.2Cash and equivalents, Q2 FY2024, at 2024-06-30$6.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure5.6Cash and equivalents, Q3 FY2024, at 2024-09-30$5.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure13.5Cash and equivalents, FY2024, at 2024-12-31$13.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure5.3Cash and equivalents, Q1 FY2025, at 2025-03-31$5.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure10.4Cash and equivalents, Q2 FY2025, at 2025-06-30$10.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure13.2Cash and equivalents, Q3 FY2025, at 2025-09-30$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure14.4Cash and equivalents, FY2025, at 2025-12-31$14.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure22.2Cash and equivalents, Q1 FY2026, at 2026-03-31$22.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure19.9Cash and equivalents, Q2 FY2026, at 2026-06-30$19.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Current assets$mnot reported23.7Current assets, FY2023, at 2023-12-31$23.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figurenot reported7.2Current assets, Q2 FY2024, at 2024-06-30$7.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure6.8Current assets, Q3 FY2024, at 2024-09-30$6.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure14.7Current assets, FY2024, at 2024-12-31$14.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure6.3Current assets, Q1 FY2025, at 2025-03-31$6.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure10.8Current assets, Q2 FY2025, at 2025-06-30$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure13.5Current assets, Q3 FY2025, at 2025-09-30$13.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure15.1Current assets, FY2025, at 2025-12-31$15.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure23.6Current assets, Q1 FY2026, at 2026-03-31$23.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure21.1Current assets, Q2 FY2026, at 2026-06-30$21.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Total assets$m5.4Total assets, Q3 FY2023, at 2023-09-30$5.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001437749-23-031973.Report this figure23.7Total assets, FY2023, at 2023-12-31$23.7m. XBRL concept us-gaap:Assets. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figure13.5Total assets, Q1 FY2024, at 2024-03-31$13.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure8.1Total assets, Q2 FY2024, at 2024-06-30$8.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure7.6Total assets, Q3 FY2024, at 2024-09-30$7.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure15.5Total assets, FY2024, at 2024-12-31$15.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure7.1Total assets, Q1 FY2025, at 2025-03-31$7.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure11.6Total assets, Q2 FY2025, at 2025-06-30$11.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure14.3Total assets, Q3 FY2025, at 2025-09-30$14.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure15.9Total assets, FY2025, at 2025-12-31$15.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure23.6Total assets, Q1 FY2026, at 2026-03-31$23.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure21.1Total assets, Q2 FY2026, at 2026-06-30$21.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Current liabilities$m17.3Current liabilities, Q3 FY2023, at 2023-09-30$17.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2024-04-15, accession 0001437749-24-011955.Report this figure17.2Current liabilities, FY2023, at 2023-12-31$17.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figure14.5Current liabilities, Q1 FY2024, at 2024-03-31$14.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure13.9Current liabilities, Q2 FY2024, at 2024-06-30$13.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure17.5Current liabilities, Q3 FY2024, at 2024-09-30$17.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure14.6Current liabilities, FY2024, at 2024-12-31$14.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure11.5Current liabilities, Q1 FY2025, at 2025-03-31$11.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure12.1Current liabilities, Q2 FY2025, at 2025-06-30$12.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure9.7Current liabilities, Q3 FY2025, at 2025-09-30$9.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure7.3Current liabilities, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure6.1Current liabilities, Q1 FY2026, at 2026-03-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure5.9Current liabilities, Q2 FY2026, at 2026-06-30$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Total liabilities$m18.2Total liabilities, Q3 FY2023, at 2023-09-30$18.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2024-04-15, accession 0001437749-24-011955.Report this figure18.0Total liabilities, FY2023, at 2023-12-31$18.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figure14.8Total liabilities, Q1 FY2024, at 2024-03-31$14.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure14.1Total liabilities, Q2 FY2024, at 2024-06-30$14.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure17.6Total liabilities, Q3 FY2024, at 2024-09-30$17.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure14.7Total liabilities, FY2024, at 2024-12-31$14.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure11.5Total liabilities, Q1 FY2025, at 2025-03-31$11.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure12.1Total liabilities, Q2 FY2025, at 2025-06-30$12.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure9.8Total liabilities, Q3 FY2025, at 2025-09-30$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure7.3Total liabilities, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure6.1Total liabilities, Q1 FY2026, at 2026-03-31$6.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure5.9Total liabilities, Q2 FY2026, at 2026-06-30$5.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Short-term borrowings$m0.2Short-term borrowings, Q3 FY2023, at 2023-09-30$222.5k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2023-11-14, accession 0001437749-23-031973.Report this figure0.0Short-term borrowings, FY2023, at 2023-12-31$0. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2025-04-03, accession 0001437749-25-010791.Report this figure0.3Short-term borrowings, Q1 FY2024, at 2024-03-31$332.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-05-14, accession 0001437749-24-016366.Report this figure0.2Short-term borrowings, Q2 FY2024, at 2024-06-30$207.5k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-08-14, accession 0001437749-24-026571.Report this figure0.1Short-term borrowings, Q3 FY2024, at 2024-09-30$83.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure0.5Short-term borrowings, FY2024, at 2024-12-31$458.2k. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure0.2Short-term borrowings, Q1 FY2025, at 2025-03-31$224.3k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure0.1Short-term borrowings, Q2 FY2025, at 2025-06-30$113.2k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure0.0Short-term borrowings, Q3 FY2025, at 2025-09-30$0. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure0.4Short-term borrowings, FY2025, at 2025-12-31$406.9k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure0.2Short-term borrowings, Q1 FY2026, at 2026-03-31$231.3k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure0.1Short-term borrowings, Q2 FY2026, at 2026-06-30$144.1k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure
Shareholders' equity$m(12.8)Shareholders' equity, Q3 FY2023, at 2023-09-30−$12.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001437749-24-035375.Report this figure5.7Shareholders' equity, FY2023, at 2023-12-31$5.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001437749-26-010126.Report this figure(1.3)Shareholders' equity, Q1 FY2024, at 2024-03-31−$1.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-14, accession 0001437749-25-026967.Report this figure(6.0)Shareholders' equity, Q2 FY2024, at 2024-06-30−$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure(10.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$10.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure0.8Shareholders' equity, FY2024, at 2024-12-31$812.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure(4.5)Shareholders' equity, Q1 FY2025, at 2025-03-31−$4.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure(0.5)Shareholders' equity, Q2 FY2025, at 2025-06-30−$459.1k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure4.5Shareholders' equity, Q3 FY2025, at 2025-09-30$4.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001437749-25-034827.Report this figure8.6Shareholders' equity, FY2025, at 2025-12-31$8.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure17.4Shareholders' equity, Q1 FY2026, at 2026-03-31$17.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure15.2Shareholders' equity, Q2 FY2026, at 2026-06-30$15.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-12, accession 0001437749-26-027358.Report this figure

Cash flow

Operating cash flow−$2.1m, Q2 FY2026
Reviva Pharmaceuticals Holdings, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(6.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001437749-24-035375. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-04-03, accession 0001437749-25-010791. Derived: 12-month figure less the 9-month figure.Report this figure(11.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$11.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0001437749-25-017191.Report this figure(8.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001437749-25-026967. Derived: 6-month figure less the 3-month figure.Report this figure(4.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034827. Derived: 9-month figure less the 6-month figure.Report this figure(9.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(8.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(5.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001437749-26-027358. Derived: 6-month figure less the 3-month figure.Report this figure(5.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034827. Derived: 9-month figure less the 6-month figure.Report this figure(5.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001437749-26-010126. Derived: 12-month figure less the 9-month figure.Report this figure(3.8)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001437749-26-016762.Report this figure(2.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001437749-26-027358. Derived: 6-month figure less the 3-month figure.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.